$12.78
0.393.13%
At Close: -
$12.65
-0.13-1.00%
After Hours: Jul 16, 8:34 AM EDT
15 minutes delayed
Comments
Loading...
Avalo Therapeutics
AVTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Avalo Therapeutics (NASDAQ:AVTX) Stock, Analyst Ratings, Price Targets, Forecasts
Avalo Therapeutics Inc has a consensus price target of $12.92 based on the ratings of 3 analysts. The high is $35 issued by Oppenheimer on April 16, 2024. The low is $0.75 issued by RBC Capital on June 27, 2023. The 3 most-recent analyst ratings were released by Oppenheimer, RBC Capital, and RBC Capital on April 16, 2024, June 27, 2023, and May 10, 2023, respectively. With an average price target of $14.92 between Oppenheimer, RBC Capital, and RBC Capital, there's an implied 17.92% upside for Avalo Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
RBC Capital
Jefferies
1calculated from analyst ratings
Analyst Ratings for Avalo Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | Buy Now | 176.68% | Oppenheimer | Leland Gershell | → $35 | Upgrade | Perform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | — | Oppenheimer | Leland Gershell | — | Downgrade | Outperform → Perform | Get Alert |
| 06/27/2023 | Buy Now | -94.07% | RBC Capital | Gregory Renza | $2160 → $180 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/10/2023 | Buy Now | -28.85% | RBC Capital | Gregory Renza | $4080 → $2160 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | -76.28% | Jefferies | Chris Howerton | → $720 | Downgrade | Hold → Underperform | Get Alert |
| 03/03/2022 | Buy Now | -94.07% | Jefferies | Chris Howerton | $14400 → $2160 | Downgrade | Buy → Hold | Get Alert |
| 03/03/2022 | Buy Now | -68.38% | RBC Capital | Gregory Renza | $14400 → $11520 | Maintains | Outperform | Get Alert |
| 09/24/2021 | Buy Now | -52.57% | RBC Capital | Gregory Renza | → $17280 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Avalo Therapeutics (AVTX) stock?
The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Oppenheimer on April 16, 2024. The analyst firm set a price target for $35.00 expecting AVTX to rise to within 12 months (a possible 176.68% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avalo Therapeutics (AVTX)?
The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Oppenheimer, and Avalo Therapeutics upgraded their outperform rating.
When was the last upgrade for Avalo Therapeutics (AVTX)?
The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.
When was the last downgrade for Avalo Therapeutics (AVTX)?
The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Avalo Therapeutics (AVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Avalo Therapeutics (AVTX) correct?
While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a upgraded with a price target of $0.00 to $35.00. The current price Avalo Therapeutics (AVTX) is trading at is $12.65, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.